|
 | There are currently no jobs available
|  |
| Pfizer announces update to its development pipeline | Posted on 28/01/2010 in Pharmaceutical Company Product News Pfizer has revealed changes to its research and development pipeline for the first time since it acquired fellow pharmaceutical firm Wyeth last October.
The new pipeline comprises assets from both organisations and includes a total of 133 programmes from phase I through to registration.
Martin Mackay, president of pharmatherapeutics research and development at Pfizer, stated that since the acquisition of Wyeth, a number of strategic decisions regarding the company's "research and development resources, global footprint and high-priority projects" have been made.
"This pipeline of investigational medicines represents the strong future of Pfizer. Our focus now turns to delivery of these health solutions for patients around the world," he furthered.
Meanwhile, Pfizer announced this week that a phase III clinical study into Sutent (sunitinib malat) - its drug designed to hinder the growth of advanced pancreatic neuroendocrine tumours - yielded promising results.Other news stories from 28/01/2010
Read more in the Zenopa News Archive
How this news is generated
|  |
|
|  | Harriet
Zenopa Account Manager
01494 818 007
(Mon to Fri 0830 to 1800 hours)
harriet@zenopa.com
| |
|
